JP5849302B2 - 三環化合物およびこれを含有するｐｂｋ阻害剤 - Google Patents

三環化合物およびこれを含有するｐｂｋ阻害剤 Download PDF

Info

Publication number
JP5849302B2
JP5849302B2 JP2013502740A JP2013502740A JP5849302B2 JP 5849302 B2 JP5849302 B2 JP 5849302B2 JP 2013502740 A JP2013502740 A JP 2013502740A JP 2013502740 A JP2013502740 A JP 2013502740A JP 5849302 B2 JP5849302 B2 JP 5849302B2
Authority
JP
Japan
Prior art keywords
quinolin
phenyl
hydroxy
hydroxythieno
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013502740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523749A5 (https=
JP2013523749A (ja
Inventor
中村　祐輔
祐輔 中村
松尾　洋
洋 松尾
昇二 久田
昇二 久田
アーメド，フェルヤン
ハントリー，レイモンド
サジャーディー−ハシェミ，ゾーレ
ジェンキンス，デヴィッド・エム
カーグボ，ロバート・ビー
クイ，ウェングェ
ガウアン，ポリビナ・ジョリシア・エフ
ウォーカー，ジョエル・アール
デコルネ，ヘレーネ
グラム，マヘンデル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2013523749A publication Critical patent/JP2013523749A/ja
Publication of JP2013523749A5 publication Critical patent/JP2013523749A5/ja
Application granted granted Critical
Publication of JP5849302B2 publication Critical patent/JP5849302B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2013502740A 2010-03-29 2011-03-29 三環化合物およびこれを含有するｐｂｋ阻害剤 Active JP5849302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31860610P 2010-03-29 2010-03-29
US61/318,606 2010-03-29
PCT/US2011/030278 WO2011123419A1 (en) 2010-03-29 2011-03-29 Trycyclic compounds and pbk inhibitors containing the same

Publications (3)

Publication Number Publication Date
JP2013523749A JP2013523749A (ja) 2013-06-17
JP2013523749A5 JP2013523749A5 (https=) 2014-05-15
JP5849302B2 true JP5849302B2 (ja) 2016-01-27

Family

ID=44712585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013502740A Active JP5849302B2 (ja) 2010-03-29 2011-03-29 三環化合物およびこれを含有するｐｂｋ阻害剤

Country Status (15)

Country Link
US (2) US8962648B2 (https=)
EP (1) EP2552206B1 (https=)
JP (1) JP5849302B2 (https=)
KR (1) KR101757502B1 (https=)
CN (1) CN102917590B (https=)
AU (1) AU2011235319B2 (https=)
BR (1) BR112012023836B1 (https=)
CA (1) CA2792941C (https=)
DK (1) DK2552206T3 (https=)
ES (1) ES2547571T3 (https=)
IL (1) IL222080B (https=)
MX (1) MX2012011412A (https=)
SG (1) SG184376A1 (https=)
TW (1) TWI503323B (https=)
WO (1) WO2011123419A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2857848T3 (es) * 2013-12-24 2021-09-29 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
TWI557011B (zh) 2015-05-25 2016-11-11 可影像處理的自行車錶裝置
KR20180011843A (ko) 2015-06-11 2018-02-02 바실리어 파마슈티카 인터내셔널 리미티드 유출-펌프 억제제 및 이의 치료적 용도
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
CN108341774B (zh) * 2017-01-25 2022-07-19 首药控股(北京)股份有限公司 取代的喹啉酮类抑制剂
EP3609869A1 (de) 2017-04-10 2020-02-19 Bayer Aktiengesellschaft Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung
WO2019094404A1 (en) * 2017-11-07 2019-05-16 Temple University-Of The Commonwealth System Of Higher Education Compositions and methods for improved t cells
CN111099941B (zh) * 2018-10-26 2022-10-18 中国科学院上海有机化学研究所 一种烷基腈类化合物的制备方法
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法
WO2024008113A1 (zh) * 2022-07-07 2024-01-11 深圳微芯生物科技股份有限公司 一种甲酰胺取代的杂三环类衍生物、其制备方法及其应用
WO2024097228A1 (en) * 2022-10-31 2024-05-10 Meliora Therapeutics, Inc. Compounds targeting cdk11 and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5377096A (en) * 1976-12-17 1978-07-08 Teijin Ltd Preparation of thieno 2,3-c quinolin-4(5h)-one-7-acetic acids
FR2636063B1 (fr) * 1988-09-05 1993-04-30 Centre Nat Rech Scient Composes phenylpyrroliques utiles en tant que medicaments, leur preparation et leur application
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
US6506769B2 (en) * 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
CA2396579A1 (en) * 1999-12-29 2001-07-05 Wyeth Tricyclic protein kinase inhibitors
DE10242106A1 (de) 2002-09-11 2004-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Phosphorgruppenhaltige Carbonsäurederivate mit organisch polymerisierbaren Gruppen
HRP20050248A2 (en) 2002-09-17 2005-10-31 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
US20040157804A1 (en) 2002-10-16 2004-08-12 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
GB0501999D0 (en) * 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US7956064B2 (en) * 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
AU2009219154A1 (en) * 2008-02-29 2009-09-03 Cylene Pharmaceuticals, Inc. Protein kinase modulators

Also Published As

Publication number Publication date
CN102917590A (zh) 2013-02-06
SG184376A1 (en) 2012-11-29
EP2552206A1 (en) 2013-02-06
RU2012145855A (ru) 2014-05-10
BR112012023836B1 (pt) 2022-02-01
HK1179114A1 (en) 2013-09-27
CN102917590B (zh) 2016-02-17
EP2552206A4 (en) 2013-08-14
CA2792941C (en) 2017-09-12
US9453025B2 (en) 2016-09-27
IL222080B (en) 2018-05-31
WO2011123419A1 (en) 2011-10-06
BR112012023836A2 (pt) 2015-09-22
DK2552206T3 (en) 2015-09-28
AU2011235319A1 (en) 2012-10-11
KR20130020666A (ko) 2013-02-27
US20130178459A1 (en) 2013-07-11
MX2012011412A (es) 2013-02-07
US8962648B2 (en) 2015-02-24
TWI503323B (zh) 2015-10-11
ES2547571T3 (es) 2015-10-07
JP2013523749A (ja) 2013-06-17
CA2792941A1 (en) 2011-10-06
KR101757502B1 (ko) 2017-07-12
AU2011235319B2 (en) 2016-07-14
EP2552206B1 (en) 2015-07-22
US20150183799A1 (en) 2015-07-02
TW201136939A (en) 2011-11-01

Similar Documents

Publication Publication Date Title
JP5849302B2 (ja) 三環化合物およびこれを含有するｐｂｋ阻害剤
EP3908585B1 (en) Imidazo[1,2-b]pyridazine il-17a inhibitors
AU2019201352B2 (en) Bromodomain inhibitors
AU2013334236B2 (en) Heteroaryl inhibitors of PDE4
CN107074787B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
CN104053661B (zh) 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂
US20030220321A1 (en) Substituted azepino[4,5b]indole derivatives
AU2007275221A1 (en) Benzothiophene inhibitors of RHO kinase
CN101622246A (zh) 可用作axl抑制剂的多环杂芳基取代的三唑
TW201446758A (zh) 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途
JP6515175B2 (ja) 芳香族ヘテロ環誘導体及びその医薬的適用
CN120641397A (zh) 稠合吡咯基磺酰胺化合物
RU2574398C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[2,3-с]ХИНОЛИНА-4-ОНА, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ РВК-ЗАВИСИМОГО ЗАБОЛЕВАНИЯ
HK1179114B (en) Tricyclic compounds and pbk inhibitors containing the same
HK40063819B (zh) Tyk2抑制剂和其用途
JPH09216823A (ja) プロラクチン産生抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151106

R150 Certificate of patent or registration of utility model

Ref document number: 5849302

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250